1 – 50 of 83
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Cancer risk in severe alpha-1-antitrypsin deficiency: the importance of early identification
(
- Contribution to journal › Article
-
Mark
The Clinical Course of Severe Alpha-1-Antitrypsin Deficiency in Patients Identified by Screening
(
- Contribution to journal › Article
-
Mark
Cancer risk in severe alpha-1-antitrypsin deficiency
(
- Contribution to journal › Article
- 2021
-
Mark
Severe alpha-1-antitrypsin deficiency increases the risk of venous thromboembolism
(
- Contribution to journal › Article
-
Mark
Lung Function and Health Status in Individuals with Severe Alpha-1-Antitrypsin Deficiency at the Age of 42
(
- Contribution to journal › Article
- 2020
-
Mark
Kardiellt troponin – en biomarkör för hjärt–kärlsjukdom vid KOL
(
- Contribution to journal › Article
-
Mark
Decreased risk of ischemic heart disease in individuals with severe alpha 1-antitrypsin deficiency (PiZZ) in comparison with the general population
(
- Contribution to journal › Article
- 2019
-
Mark
Liver disease in adults with severe alpha-1-antitrypsin deficiency
(
- Contribution to journal › Article
-
Mark
Survival in the Swedish cohort with alpha-1-antitrypsin deficiency, up to the age of 43-45 years
(
- Contribution to journal › Article
-
Mark
Decline in FEV1 and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency
(
- Contribution to journal › Article
-
Mark
Oscillometry in Chronic Obstructive Lung Disease : In vitro and in vivo evaluation of the impulse oscillometry and tremoflo devices
(
- Contribution to journal › Article
-
Mark
Efficacy and safety of inhaled α1-antitrypsin in patients with severe α1-antitrypsin deficiency and frequent exacerbations of COPD
(
- Contribution to journal › Article
- 2018
-
Mark
Deposition of inhaled nanoparticles is reduced in subjects with COPD and correlates with the extent of emphysema : Proof of concept for a novel diagnostic technique
(
- Contribution to journal › Article
-
Mark
Lung function and CT lung densitometry in 37-to 39-year-old individuals with alpha-1-antitrypsin deficiency
(
- Contribution to journal › Article
- 2017
-
Mark
Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency : an open-label extension trial (RAPID-OLE)
(
- Contribution to journal › Article
-
Mark
Health status and lung function in the Swedish alpha 1-antitrypsin deficient cohort, identified by neonatal screening, at the age of 37-40 years
(
- Contribution to journal › Article
-
Mark
European Respiratory Society statement : Diagnosis and treatment of pulmonary disease in α1-antitrypsin deficiency
(
- Contribution to journal › Article
-
Mark
Survival in individuals with severe alpha 1-antitrypsin deficiency (PiZZ) in comparison to a general population with known smoking habits
(
- Contribution to journal › Article
-
Mark
Liver function in alpha-1-antitrypsin deficient individuals at 37 to 40 years of age
(
- Contribution to journal › Article
- 2016
-
Mark
Vital capacity and COPD : The Swedish CArdioPulmonary bioImage Study (SCAPIS)
(
- Contribution to journal › Article
-
Mark
Cause-specific mortality in individuals with severe alpha 1-antitrypsin deficiency in comparison with the general population in Sweden
(
- Contribution to journal › Article
-
Mark
Recovery of inhaled nanoparticles, airflow obstruction and emphysema
2016) European Respiratory Society (ERS) Congress 2016(
- Contribution to conference › Abstract
- 2015
-
Mark
Lung Function and CT Densitometry in Subjects with alpha-1-Antitrypsin Deficiency and Healthy Controls at 35 Years of Age.
(
- Contribution to journal › Article
-
Mark
Chronic Obstructive Pulmonary Disease Is Common in Never-smoking Patients with Primary Sjögren Syndrome.
(
- Contribution to journal › Article
-
Mark
The Clinical Profile of Subjects Included in the Swedish National Register on Individuals with Severe Alpha 1-Antitrypsin deficiency.
(
- Contribution to journal › Article
-
Mark
Relationship between Change in Lung Density and Long-Term Progression of Lung Function.
(
- Contribution to journal › Letter
-
Mark
Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
(
- Contribution to journal › Article
-
Mark
The Swedish Alpha 1-antitrypsin Screening Study: Health Status, Lung and Liver Function at Age 34.
2015) In Annals of the American Thoracic Society(
- Contribution to journal › Article
-
Mark
Using nanoparticles to detect emphysema
2015) European respiratory society international congress 2015(
- Contribution to conference › Abstract
-
Mark
Exhaled nanoparticles to detect emphysema
2015) The Fleischner Society annual meeting 2015(
- Contribution to conference › Abstract
- 2014
-
Mark
The forced oscillation technique is a sensitive method for detecting obstructive airway disease in patients with primary Sjögren's syndrome.
(
- Contribution to journal › Article
-
Mark
Survival benefit of lung transplantation for chronic obstructive pulmonary disease in sweden.
(
- Contribution to journal › Article
- 2012
-
Mark
Frequent development of chronic obstructive pulmonary disease in primary SS--results of a longitudinal follow-up.
(
- Contribution to journal › Article
-
Mark
Randomised controlled trial for emphysema with a selective agonist of the gamma-type retinoic acid receptor
(
- Contribution to journal › Article
- 2011
-
Mark
Alpha-1-antitrypsin deficiency and periodontitis, a pilot study
(
- Contribution to journal › Article
-
Mark
Eureka?
(
- Contribution to journal › Letter
-
Mark
The fibrinogen cleavage product A alpha-Val(360), a specific marker of neutrophil elastase activity in vivo
(
- Contribution to journal › Article
-
Mark
CT lung densitometry in young adults with alpha-1-antitrypsin deficiency
(
- Contribution to journal › Article
-
Mark
Survival benefit of lung transplantation in individuals with severe α(1)-anti-trypsin deficiency (PiZZ) and emphysema.
(
- Contribution to journal › Article
-
Mark
Performance of enhanced liver fibrosis plasma markers in asymptomatic individuals with ZZ α1-antitrypsin deficiency.
(
- Contribution to journal › Article
- 2010
-
Mark
Plasma levels of TIMP-1 are higher in 34-year-old individuals with severe alpha 1-antitrypsin deficiency
(
- Contribution to journal › Letter
-
Mark
Survival in severe alpha-1-antitrypsin deficiency (PiZZ)
(
- Contribution to journal › Article
-
Mark
Therapeutic efficacy of alpha-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry
(
- Contribution to journal › Article
- 2009
-
Mark
Validity of apparent diffusion coefficient hyperpolarized He-3-MRI using MSCT and pulmonary function tests as references
(
- Contribution to journal › Article
-
Mark
Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha(1)-antitrypsin deficiency
(
- Contribution to journal › Article
-
Mark
Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency
(
- Contribution to journal › Article
-
Mark
Progression of Emphysema in a 12-month Hyperpolarized (3)He-MRI Study Lacunarity Analysis Provided a More Sensitive Measure than Standard ADC Analysis(1).
(
- Contribution to journal › Article
-
Mark
Lung function in 30-year-old alpha-1-antitrypsin-deficient individuals.
(
- Contribution to journal › Article
-
Mark
Dark adaptation during systemic hypoxia induced by chronic respiratory insufficiency
(
- Contribution to journal › Article
-
Mark
The liver in 30-year-old individuals with alpha(1)-antitrypsin deficiency.
(
- Contribution to journal › Article